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Abstract
Juvenile idiopathic arthritis (JIA) is a heterogeneous autoimmune
disease characterized by chronic joint inflammation. Knowing
which antigens drive the autoreactive T-cell response in JIA is
crucial for the understanding of disease pathogenesis and
additionally may provide targets for antigen-specific immune
therapy. In this study, we tested 9 self-peptides derived from
joint-related autoantigens for T-cell recognition (T-cell
proliferative responses and cytokine production) in 36 JIA
patients and 15 healthy controls. Positive T-cell proliferative
responses (stimulation index ≥2) to one or more peptides were
detected in peripheral blood mononuclear cells (PBMC) of 69%
of JIA patients irrespective of major histocompatibility complex
(MHC) genotype. The peptides derived from aggrecan, fibrillin,
and matrix metalloproteinase (MMP)-3 yielded the highest
frequency of T-cell proliferative responses in JIA patients. In both
the oligoarticular and polyarticular subtypes of JIA, the aggrecan
peptide induced T-cell proliferative responses that were
inversely related with disease duration. The fibrillin peptide, to
our knowledge, is the first identified autoantigen that is primarily
recognized in polyarticular JIA patients. Finally, the epitope
derived from MMP-3 elicited immune responses in both
subtypes of JIA and in healthy controls. Cytokine production in
short-term peptide-specific T-cell lines revealed production of
interferon-γ (aggrecan/MMP-3) and interleukin (IL)-17
(aggrecan) and inhibition of IL-10 production (aggrecan). Here,
we have identified a triplet of self-epitopes, each with distinct
patterns of T-cell recognition in JIA patients. Additional
experiments need to be performed to explore their qualities and
role in disease pathogenesis in further detail.
Introduction
Juvenile idiopathic arthritis (JIA) is a heterogeneous autoim-
mune disease of childhood and is characterized by chronic
inflammation of one or more joints [1,2]. Inflammation in the
joint is characterized by a selected accumulation in the syn-
ovium of activated T cells, which are clustered around antigen-
presenting (dendritic) cells [3,4]. Oligoclonal expansions of T
cells are present in synovial fluid as compared with peripheral
AA = adjuvant arthritis; BLAST = Basic Local Alignment Search Tool; cpm = counts per minute; ECM = extracellular matrix; FCS = fetal calf serum; 
FITC = fluorescein isothiocyanate; HLA = human leukocyte antigen; HPLC = high performance liquid chromatography; IFN-γ = interferon-γ; IL = inter-
leukin; JIA = juvenile idiopathic arthritis; MHC = major histocompatibility complex; MMP = matrix metalloproteinase; PBMC = peripheral blood mono-
nuclear cells; PBS = phosphate-buffered saline; PE = phycoerythrin; RA = rheumatoid arthritis; SI = stimulation index; SMPS = simultaneous multiple 
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blood and these T cells show an activated, highly differenti-
ated memory phenotype that implies selective recruitment
from the blood [5,6]. In addition, JIA has strong associations
with multiple human leukocyte antigen (HLA) genes, class II
associations being more numerous than the few documented
class I associations [1,7-10]. Altogether, this supports the
concept of an ongoing antigen-driven immune response with
a central role for autoreactive T cells recognizing antigens that
are expressed in the joint in the context of HLA.
Knowing which antigens drive or control autoreactive T-cell
responses in JIA is important for our understanding of the role
of T cells in disease pathogenesis. In addition, identification of
such self-epitopes may provide us with tools to monitor JIA-
specific T-cell responses during the course of the disease, and
may become targets for antigen-specific immune therapy. At
present, only a limited number of self-antigens involved in JIA
disease pathogenesis are known [11-15]. A popular and
attractive hypothesis on how autoreactive T cells can trigger
autoimmune pathology is the 'molecular mimicry' scenario:
activation of autoreactive lymphocytes by structurally similar
antigenic determinants of infectious pathogens [16,17].
Molecular mimicry at the level of CD4+ T cells is suggested to
be involved in several autoimmune diseases, including JIA
[14,18-24], although definite proof for such a mechanism is
lacking in most cases [17].
The aim of the present study was to identify joint-related self-
antigens that induce T-cell reactivity in patients with JIA. The
self-epitopes tested in this study were recently identified as T-
cell epitopes recognized during adjuvant arthritis (AA) [25].
AA is an experimental rat model for chronic arthritis with
resemblance to JIA and rheumatoid arthritis (RA) [26]. The
novel T-cell epitopes were selected with an elaborate compu-
ter search strategy based on the alleged molecular mimicry
scenario as a cause for disease induction in AA [25]. Previ-
ously, a selection of human homologs of these epitopes were
tested for T-cell recognition in patients with RA [27]. Based on
the T-cell responses noted in AA and RA, we selected a set of
nine human homologs of the identified self-epitopes and
tested them for T-cell recognition in patients with JIA. All
epitopes were conserved, differing by at most three amino
acids between the rat and human sequences.
We found that self-epitopes derived from aggrecan, fibrillin,
and matrix metalloproteinase (MMP)-3 induced in patients
with JIA significant T-cell responses that were related to dis-
ease duration and disease subtype. In contrast to the epitopes
derived from aggrecan and fibrillin, the MMP-3-derived
epitope was also recognized in healthy controls. Restimulated
peptide-specific T-cell lines of patients with polyarticular JIA
showed production of interferon-γ (IFN-γ)/interleukin (IL)-17
and inhibition of IL-10 production. Here, we have identified a
triplet of self-epitopes derived from joint-related structures and




We obtained blood from 36 JIA patients who fulfilled the diag-
nostic criteria of oligoarticular and polyarticular (including
extended oligoarticular) onset types [28]. Patient characteris-
tics are presented in Table 1. We obtained blood from 15
healthy children (age range 3.0 to 12.6 years, median 7.0
years; 7 male, 8 female), who were undergoing minor surgical
procedures, as controls. Informed consent was obtained from
all children or their parents. The local medical ethics review
board approved the study.
Peptide selection and synthesis
The joint-related self-epitopes were selected on the basis of
the molecular mimicry computer search described by van
Bilsen and colleagues [25]. Briefly, the interaction of the myco-
bacterial heat-shock protein 65 (HSP65) 178–186 peptide
with rat major histocompatibility complex (MHC) class II
(RTl.BL) and the T-cell receptor (TCR) of an arthritogenic T-cell
clone was used as a mold for the identification of fitting self-
epitopes. Because it is still debated whether T-cell epitopes
derived from autoantigens display high or low affinity for their
MHC restriction element, the search profile was designed to
select peptides with a broad range of affinities to RTl.BL [29-
31]. Based on the T-cell responses noted in AA and RA
[27,32], we selected a set of nine human homologs of the
identified self-epitopes and tested them for T-cell recognition
in patients with JIA. Peptide characteristics are shown in Table
2.
The peptides were synthesized as 15-mers via automated
simultaneous multiple peptide synthesis (SMPS). The SMPS
set-up was developed using a standard auto sampler (Gilson
221) as described previously [33]. Briefly, standard Fmoc
chemistry with in situ PyBop/NMM activation of the amino
acids in fivefold molar excess with respect to 2 μmol/peptide
PAL-PEG-PS resin (PerSeptive Biosystems, now part of
Applied Biosystems, Foster City, CA, USA) was employed.
Peptides were obtained as C-terminal amides after cleavage
with 90%–95% TFA/scavenger cocktails. Peptides were ana-
lyzed and purified by reverse-phase high performance liquid
chromatography (HPLC) and checked via electrospray ioniza-
tion mass spectrometry (LCQ; Thermoquest, now part of
Thermo Electron Corporation, Waltham, MA, USA). If peptide
purity was less than 95%, peptides were purified on reverse-
phase HPLC before use.
T-cell proliferation assays
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll Paque (Amersham Pharmacia Biotech, now part of GE
Healthcare, Little Chalfont, Buckinghamshire, UK) density gra-
dient centrifugation of heparinized blood. Cells were washedAvailable online http://arthritis-research.com/content/8/6/R178
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and cultured in RPMI-1640 supplemented with 2 mM
glutamine, 100 U/ml of penicillin/streptomycin (Gibco BRL,
now part of Invitrogen Corporation, Carlsbad, CA, USA), and
10% (by volume) ABpos heat-inactivated (60 minutes at 56°C)
human serum (Sanquin Blood Bank, Utrecht, The Nether-
lands). Cells were cultured in triplicate (2 × 105 cells in 200 μl
per well) in round-bottomed 96-well plates (NUNC A/S,
Roskilde, Denmark) for 120 hours at 37°C in 5% CO2 with
100% relative humidity, in the absence or presence of 20 μg/
ml peptide. These concentrations were found to be optimal in
preliminary dose-response experiments (data not shown).
Concanavalin A (2.5 μg/ml; Calbiochem, San Diego, CA,
USA) and tetanus-toxoid (1.5 μg/ml; RIVM, Bilthoven, The
Netherlands) were used as positive controls. A mouse class II
restricted epitope (OVA 323–339) was used as an irrelevant
control peptide. During the last 16 hours of culture, 1 μCi (37
kBq) 3H-thymidine (ICN Biomedicals, now part of MP Biomed-
icals, Irvine, CA, USA) was added to each well. Cells were har-
vested according to standard procedures, and incorporated
radioactivity was measured by liquid scintillation counting and
expressed as counts per minute (cpm). The magnitude of the
proliferative response was expressed as stimulation index (SI),
Table 1
Characteristics of patients with JIA
JIA Oligoarticular JIA Polyarticular JIA
Number 36 16 (44%) 20 (56%)
Male/Female 9/27 (25%/75%) 3/13 (19%/81%) 6/14 (30%/70%)
Age range in years (median) 3.5–18.9 (11.4) 3.5–16.6 (11.7) 4.9–18.9 (10.9)
Disease durationa 5.1 (3.3) 5.2 (4.0) 5.0 (2.8)
Disease activity (active/remission) 22/14 (61%/39%) 9/7 (56%/44%) 13/7 (65%/35%)
RF-positive 2 (6%) 0 2 (10%)
ANA-positive 21 (58%) 11 (69%) 10 (50%)
Uveitis 3 (8%) 2 (13%) 1 (5%)
NSAID use 30 (83%) 11 (69%) 19 (95%)
Sulfasalazine and/or methotrexate 
use
10 (28%) 2 (13%) 8 (40%)
aExpressed in years as mean (standard deviation). Disease duration at the time of sampling was defined as the time that passed since the first 
disease-related symptom (arthritis). The presence of joint swelling or limitation of movement with either pain on movement or tenderness defined 
active disease. The absence of joint swelling or limitation of movement with either pain on movement or tenderness defined disease remission. 
None of the patients was treated with prednisone, anti-tumor necrosis factor-α, or anti-interleukin-1 therapy. ANA, anti-nuclear antigen; JIA, 
juvenile idiopathic arthritis; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor.
Table 2
Characteristics of the peptides derived from joint-related structures
Protein Sequence Positiona Abbreviation
Aggrecan core protein precursor LSGLPSGGEVLEISV 1,352–1,366 aggrecan
Aggrecan core protein precursor ISGLPSGGDDLETST 924–938 aggrecan3
Calpain-2 HAYSVTGAEEVESNG 262–276 calpain
Fibrillin-1 precursor CVDTRSGNCYLDIRP 1,526–1,540 fibrillin
Matrix metalloproteinase-1 GVVSHSFPATLETQE 14–28 MMP-1
Matrix metalloproteinase-3 FFYFFTGSSQLEFDP 446–460 MMP-3
Matrix metalloproteinase-10 SAFWPSLPSGLDAAY 329–343 MMP-10
Matrix metalloproteinase-16 VKEGHSPPDDVDIVI 539–553 MMP-16
Tenascin EPVSGSFTTALDGPS 1,789–1,803 tenascin
aAmino acid numbering according to the Swiss Protein Database. All peptides fulfill the computer search criteria described by van Bilsen and 
colleagues [25].Arthritis Research & Therapy    Vol 8 No 6    Kamphuis et al.
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which is calculated as the mean cpm of cells cultured with
antigen divided by the mean cpm of cells cultured without
antigen.
Analysis of peptide-induced cytokine production by 
multiplexed particle-based flow cytometric assay
T-cell cultures were performed as described above with
PBMC of 24 patients with JIA and 12 healthy controls. After
96 hours, cell culture supernatants were collected and stored
at -80°C. Cytokine concentrations were measured with the
Bio-Plex system in combination with the Bio-Plex Manager
software, version 3.0 (Bio-Rad Laboratories, Inc., Hercules,
CA, USA), which employs the Luminex xMAP technology as
previously described [34-37]. Briefly, this technology uses
pairs of antibodies directed against non-competing epitopes
of their respective analytes. One of the antibodies is covalently
bound to a fluorescence-emitting microsphere (λ1 and λ2) and
the other biotinylated antibody is bound to streptavidin-phyco-
erythrin (PE) (λ3). The two-dimensional signal (λ1 and λ2) dis-
criminates between up to 100 different microspheres in a
single sample. The second signal (λ3) quantifies the exact
amount of a particular microsphere in a sample. Fluorescent
intensity of the microsphere complex was measured in a final
volume of 100 μl of high performance enzyme-linked immuno-
sorbent assay buffer. The antibody pairs were purchased and
coupled as previously described [35,37]. Peptide-specific
cytokine production is calculated as the cytokine production of
cells cultured with peptide subtracted by the cytokine produc-
tion of cells cultured without peptide. The following cytokines
were measured: IL-1α, IL-1β, IL-5, IL-10, IL-12, IL-18, tumor
necrosis factor-α (TNF-α), and IFN-γ.
Cytokine analysis by lymphocyte intracellular staining 
and flow cytometry
T-cell cultures were performed as described above for 72
hours with 4 × 105 cells in 200 μl per well using PBMC from
14 patients with JIA and 6 healthy controls. During the last 5
hours of culture, Golgistop (BD Biosciences, San Jose, CA,
USA) was added (2 μM final concentration). The cells were
harvested, washed in cold phosphate-buffered saline (PBS)
with 2% fetal calf serum (FCS), blocked in PBS with 10%
FCS for 20 minutes at 4°C, washed twice, and stained with
CyChrome-conjugated anti-CD4 for 20 minutes at 4°C. Sub-
sequently, the cells were fixed in Cytofix/Cytoperm solution
(BD Biosciences) for 20 minutes at 4°C and washed twice in
Perm/Wash solution (BD Biosciences). After the second
wash, the cells were resuspended in 50 μl of Perm/Wash
solution containing a predetermined optimal concentration of
PE-conjugated anti-IL-10, PE-conjugated anti-IL-4, fluorescein
isothiocyanate (FITC)-conjugated anti-IFN-γ, and FITC-conju-
gated anti-TNF-α. After incubation for 30 minutes at 4°C, cells
were washed twice. Stained mononuclear cells were diluted in
sheath fluid and run on a FACSCalibur flow cytometer (BD
Biosciences). CellQuest software (BD Biosciences) was used
for analysis.
Short-term T-cell lines
PBMC from five patients with polyarticular JIA were cultured in
RPMI-1640 supplemented with 2 mM glutamine, 100 U/ml of
penicillin/streptomycin (Gibco BRL, now part of Invitrogen
Corporation), and 10% ABpos heat-inactivated (60 minutes at
56°C) human serum (Sanquin Blood Bank) at 2 × 105 cells per
well in the presence of 20 μg/ml peptide (aggrecan, MMP-3,
fibrillin). On days 4, 8, and 12, the culture medium was
refreshed and IL-2 (40 U/ml; Roche, Almere, The Netherlands)
was added. The cells were restimulated with peptide (20 μg/
ml) on day 10. After a total of 14 days of culture, the cells were
harvested and stained with CD3 (clone SK3), IFN-γ (clone
4S.B3), and IL-10 (clone JES3-19F1; all BD Biosciences) for
fluorescence-activated cell sorting analysis as described
above. In addition, culture supernatants were collected and
analyzed with multiplexed particle-based flow cytometric
assay (as described above) for production of cytokines (IL-1α,
IL-1β, IL-4, IL-10, IL-17, TNF-α, IFN-γ, and CXCL8).
HLA typing
Eleven patients with JIA (three oligoarticular JIA, eight polyar-
ticular JIA) were HLA-typed for HLA class II antigens DRB1,
DRB3-5, and DQB1 by PCR-SSP (polymerase chain reaction-
sequence-specific primer) according to the manufacturer's
protocol (GenoVision, Vienna, Austria).
Statistical analysis
Statistical evaluation was performed using SPSS software,
version 12.0 (SPSS Inc., Chicago, IL, USA). Basic descriptive
statistics were used to describe the patient population. Group
differences were analyzed with the Mann-Whitney U  test.
Group differences were adjusted for possible confounders
(age and gender) using linear regression with a group indica-
tor. A p value of less than 0.05 was considered statistically
significant.
Results
T-cell recognition of aggrecan, fibrillin, and MMP-3
Positive T-cell proliferative responses (SI ≥ 2) to one or more
peptides were detected in PBMC from 25 of 36 patients with
JIA (69%). The peptides derived from aggrecan, fibrillin, and
MMP-3 yielded the highest frequency of T-cell proliferative
responses in patients with JIA (Figure 1). Proliferative
responses to the aggrecan and fibrillin peptides were
significantly different from those induced in PBMC from
healthy controls (aggrecan, p = 0.015; fibrillin, p = 0.005) (Fig-
ure 2). Adjustment for age and gender did not explain these
differences. Positive proliferative responses to the MMP-3
peptide were detected in PBMC from both patients with JIA
and healthy controls.
Further analysis of the 25 JIA patients with positive T-cell
responses to one or more peptides revealed that 11 JIA
patients (44%) responded to 1 of 9 peptides, 3 JIA patients
(12%) responded to 2 of 9 peptides, 8 JIA patients (32%)Available online http://arthritis-research.com/content/8/6/R178
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responded to 3 of 9 peptides, and 3 JIA patients (12%)
responded to 4 of 9 peptides. All JIA patients with positive T-
cell responses to two or more peptides responded to variable
peptide combinations (data not shown). In addition, we did not
note any correlation between JIA patients with positive T-cell
responses to two or more peptides and disease subtype or
disease duration. Two patients with rheumatoid factor-positive
JIA were included in the study; one patient did not respond to
any of the tested peptides, and the other responded to three
peptides (aggrecan, calpain, and MMP-16).
Patients with JIA are known to have polymorphic MHC geno-
types [1], which was confirmed via HLA-class II genotyping of
selected JIA in our study. In addition, we found no correlation
between the induced T-cell proliferative responses and the
HLA-class II type of individual patients (data not shown).
T-cell responses to aggrecan and fibrillin are related to 
disease subtype
To investigate whether the recorded positive T-cell prolifera-
tive responses were related to JIA subtype, we split the JIA
patient group into the oligoarticular and polyarticular subtypes
Figure 1
Percentage of patients with juvenile idiopathic arthritis (JIA) and healthy controls showing positive T-cell proliferative responses Percentage of patients with juvenile idiopathic arthritis (JIA) and healthy controls showing positive T-cell proliferative responses. Transparent bar: 2 ≤ 
stimulation index (SI) < 3; black bar: 3 ≤ SI < 4; gray bar: SI ≥ 4. The highest frequencies were found for the peptides derived from aggrecan, fibrillin, 
and matrix metalloproteinase (MMP)-3.
Figure 2
T-cell proliferative responses in patients with juvenile idiopathic arthritis (JIA) and healthy controls T-cell proliferative responses in patients with juvenile idiopathic arthritis (JIA) and healthy controls. Proliferative responses are presented as interquar-
tile range for each group of data, with horizontal lines showing the median. The aggrecan and fibrillin peptides induced significant differences in 
responses of peripheral blood mononuclear cells (PBMC) from patients with JIA and healthy controls and are indicated as follows: **p = 0.005, *p = 
0.015. The matrix metalloproteinase (MMP)-3 peptide induced proliferative responses in PBMC of patients with JIA as well as in PBMC of controls. 
Transparent boxes: JIA; gray boxes: healthy controls.Arthritis Research & Therapy    Vol 8 No 6    Kamphuis et al.
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(Figure 3). With regard to the aggrecan peptide, proliferative
responses of PBMC from both oligoarticular as well as polyar-
ticular JIA patients were significantly increased compared with
healthy controls (oligoarticular JIA versus healthy controls: p =
0.036; polyarticular JIA versus healthy controls: p = 0.034).
Positive T-cell proliferative responses (SI ≥ 2) were detected
in 10 patients with JIA (n = 33): 4 patients with oligoarticular
JIA (SI range 2.3 to 2.8) and 6 with polyarticular JIA (SI range
2.1 to 5.8).
In contrast, the positive proliferative responses induced by the
fibrillin peptide were detected primarily in PBMC of patients
with polyarticular JIA (polyarticular JIA versus healthy controls:
p < 0.0001; polyarticular JIA versus oligoarticular JIA: p =
0.003). Positive T-cell proliferative responses (SI ≥ 2) were
detected in 9 patients with JIA (n = 35): 2 patients with oli-
goarticular JIA (SI 2.0 in both) and 7 with polyarticular JIA (SI
range 2.2 to 3.0). When comparing T-cell proliferative
responses to the fibrillin peptide in oligoarticular JIA patients
with those induced in PBMC of healthy controls, we could not
detect a significant difference between the groups (p = 0.21),
with low mean SI values in both groups (mean SI <1.4).
Positive T-cell proliferative responses (SI ≥ 2) to the MMP-3
peptide were detected in 16 of 36 patients with JIA (SI range
2 to 5.5) and 5 of 15 healthy controls (SI range 2 to 5.9). No
significant differences in T-cell proliferative responses to the
MMP-3 peptide were detected between the JIA subgroups or
between the JIA subgroups and healthy controls.
T-cell responses to aggrecan are related to disease 
duration
Furthermore, we analyzed whether proliferative responses to
the aggrecan, fibrillin, and MMP-3 peptides were related to
age, disease activity, or disease duration. When proliferative
activity was dichotomized (SI-non-responsive < 2 ≤ SI-respon-
sive), it appeared that responders to the aggrecan peptide had
the lowest disease duration (p  = 0.016) (Figure 4). With
regard to the MMP-3 peptide, we found a similar trend, which
was close to reaching statistical significance (p = 0.056). No
difference in disease duration was seen between responders
and non-responders to the fibrillin peptide. We could not find
a relation between responders to the aggrecan, fibrillin, MMP-
3 peptides and age (JIA patients or healthy controls) or dis-
ease activity (JIA patients) (data not shown).
Peptide-specific induction of cytokines
Because the aggrecan, fibrillin, and MMP-3 peptides induced
the strongest proliferative responses, these peptides were
selected to analyze cytokine production of PBMC from
patients with JIA and healthy controls upon peptide incubation.
Using the multiplex method for cytokine analysis of
supernatants taken after 96 hours of T-cell culture, we were
not able to detect peptide-specific cytokine production (all
mean values of IL-1α, IL-1β, IL-5, IL-10, IL-12, IL-18, TNF-α, or
IFN-γ less than 2.0 pg/ml in patients with JIA and healthy con-
trols). In addition, we performed T-cell activation assays for 72
hours and measured peptide-specific IL-4, IL-10, TNF-α, and
IFN-γ production by lymphocyte intracellular staining and flow
cytometry. With this technique, we did find peptide-specific
induction of either cytokine, but the differences were marginal
Figure 3
Relation of disease subtype and T-cell proliferative responses induced  by aggrecan, fibrillin, and matrix metalloproteinase (MMP)-3 Relation of disease subtype and T-cell proliferative responses induced 
by aggrecan, fibrillin, and matrix metalloproteinase (MMP)-3. Prolifera-
tive responses to the aggrecan peptide of peripheral blood mononu-
clear cells (PBMC) from both oligoarticular and polyarticular juvenile 
idiopathic arthritis (JIA) patients differed significantly with those from 
healthy controls (p = 0.034 and p = 0.036, respectively). Only PBMC 
from patients with polyarticular JIA showed significant T-cell prolifera-
tive responses to the fibrillin peptide (p < 0.0001 versus healthy con-
trols, p = 0.003 versus oligoarticular JIA). Positive proliferative 
responses to the MMP-3 peptide were seen in both JIA subgroups and 
healthy controls. Black bars: oligoarticular JIA; gray bars: polyarticular 
JIA; transparent bars: healthy controls. Asterisks indicate significant 
difference.
Figure 4
Relation of disease duration and T-cell proliferative responses induced  by aggrecan, fibrillin, and matrix metalloproteinase (MMP)-3 Relation of disease duration and T-cell proliferative responses induced 
by aggrecan, fibrillin, and matrix metalloproteinase (MMP)-3. Prolifera-
tive activity of peripheral blood mononuclear cells from patients with 
juvenile idiopathic arthritis was dichotomized as follows: stimulation 
index (SI)-non-responsive < 2 ≤ SI-responsive. Responders to the 
aggrecan peptide had the lowest disease duration (p = 0.016). 
Responders to the MMP-3 peptide showed a similar trend, which was 
close to reaching statistical significance (p = 0.056). Black bars: 
responders; transparent bars: non-responders. Asterisk indicates sig-
nificant difference.Available online http://arthritis-research.com/content/8/6/R178
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in comparison with the unstimulated PBMC and were present
only in a minority of individuals (data not shown).
To further elaborate on potential peptide-specific cytokine pro-
duction, we generated short-term peptide-specific (aggrecan,
fibrillin, or MMP-3) T-cell lines of PBMC from five patients with
polyarticular JIA. After 14 days of culture with repetitive pep-
tide stimulation, supernatants were collected and cells were
harvested. Analysis of supernatants revealed peptide-specific
cytokine production (Figure 5). The aggrecan peptide induced
the most pronounced profile of cytokines with induction of IL-
17 and IFN-γ and inhibition of IL-10 production (p < 0.05 in all
cases). In addition, the MMP-3 peptide induced significant
production of IFN-γ ( p  < 0.05). Lymphocyte (intracellular)
staining with CD3 and IFN-γ in combination with flow cytome-
try confirmed the activation of T cells in all cell lines. Repre-
sentative examples are shown in Figure 5.
Discussion
This study was conducted to identify epitopes derived from
joint-related autoantigens that induce T-cell reactivity in
patients with JIA. We recorded significant T-cell recognition of
self-epitopes derived from aggrecan, fibrillin, and MMP-3 in
patients with JIA irrespective of MHC genotype. Each of these
self-epitopes shows a distinct profile of T-cell recognition in
JIA and in health.
The proteoglycan aggrecan is one of the major constituents of
the extracellular matrix (ECM). Degradation products of aggre-
can can be detected in body fluids, including synovial fluid,
where they reflect aggrecan turnover [38,39]. Previous stud-
ies show that the proteoglycan aggrecan is a target for auto-
reactive T cells in RA and ankylosing spondylitis [40-42]. Here,
we demonstrate that aggrecan activates autoreactive T cells in
JIA as well. T-cell proliferative responses to the aggrecan pep-
tide identified were independent of JIA subtype and signifi-
cantly different from those induced in healthy controls. It is well
known that autoimmune disease progression is accompanied
by an accumulation of neo-autoreactivity directed against tar-
get determinants not involved in disease initiation, a process
known as epitope-spreading, while spontaneous regression of
primary autoreactivity can occur [43,44]. We noted an inverse
relation between responders to the aggrecan peptide and dis-
ease duration, which suggests that the aggrecan peptide in
particular could be a target of primary autoreactivity. The
induction of the pro-inflammatory cytokines IFN-γ/IL-17 and
inhibition of the anti-inflammatory cytokine IL-10 indeed sug-
gest the induction of autoaggressive T cells.
Fibrillins, also part of the ECM, are believed to guide elas-
togenesis and are involved in tissue homeostasis and morpho-
genesis. Fibrillin can be detected in the synovial lining of joints
in health and disease [45]. Remarkably, T-cell proliferative
Figure 5
Cytokine production in short-term peptide-specific T-cell lines from patients with juvenile idiopathic arthritis (JIA) Cytokine production in short-term peptide-specific T-cell lines from patients with juvenile idiopathic arthritis (JIA). Short-term peptide-specific T-cell 
lines were generated from peripheral blood mononuclear cells of five patients with polyarticular JIA. After 14 days of culture, supernatants were 
taken for multiplex cytokine analysis and cells were stained for fluorescence-activated cell sorting (FACS) analysis. The aggrecan peptide induced 
significant production of interferon-γ (IFN-γ)/interleukin (IL)-17 and inhibition of IL-10 production (p < 0.05). The matrix metalloproteinase (MMP)-3 
peptide induced significant production of IFN-γ. FACS analysis confirmed the presence of activated T cells. Asterisks indicate significant difference.Arthritis Research & Therapy    Vol 8 No 6    Kamphuis et al.
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responses to fibrillin are found primarily in polyarticular JIA
independent of disease duration. A possible explanation for
this observation may be a limited availability of fibrillin epitopes
presented in oligoarticular JIA and healthy controls due to min-
imal or no joint destruction. To our knowledge, this is the first
time that an autoantigen is described that primarily drives auto-
reactive T-cell responses in the more severe subtype of JIA,
namely polyarticular JIA, and this autoreactivity is persistent
throughout the disease course.
The MMPs are thought to be key enzymes involved in remod-
eling of the ECM in physiological and pathological situations.
New views on the function of MMPs, however, indicate that
this family of enzymes regulates various inflammatory and
repair processes; matrix degradation is only one among the
many functions that MMPs have [46]. MMP-3 is expressed in
both JIA and normal synovial tissue, and its expression corre-
lates with the degree of inflammation [47]. Recent studies
identified MMP-3 as a target for T-cell recognition in both
experimental arthritis and RA but also in age-matched healthy
adult controls [27,32]. In line with these findings, we now dem-
onstrate that the epitope derived from MMP-3 induces T-cell
proliferative responses in both patients with JIA and age-
matched healthy children as well. The universal recognition of
the MMP-3 epitope in JIA, RA, and healthy controls (adults and
children) underlines the role of MMP-3 as a target for the
immune response in health and chronic arthritis. Analysis of
cytokine induction via MMP-3-specific short-term T-cell lines
showed primarily production of IFN-γ. This may suggest a dis-
ease-promoting role of MMP-3-specific T cells in JIA. Further
studies will be necessary to determine the relevance of this
finding for the pathogenesis of JIA.
Although the method of peptide selection using 'predicted'
sequences in AA as a mold is slightly unusual and evidently
may not yield even a semi-complete list of potential peptide
sequences, the positive results support this concept. The
molecular mimicry may be a critical component of T-cell
responses to peptide sequences of joint-related antigens. An
extensive BLAST (Basic Local Alignment Search Tool) search,
however, looking for foreign peptides with an obvious
sequence homology to the aggrecan, fibrillin, or MMP-3 pep-
tide, did not yield positive results. As such, this does not sup-
port the 'molecular mimicry' hypothesis. On the other hand, it
is now known that a single TCR can recognize multiple pep-
tides that may share only one contact residue [48]. Clearly,
when using this definition of molecular mimicry, our BLAST
search must have been incomplete and potential mimicry
epitopes must have been missed.
We analyzed T-cell responses to self-peptides derived from
locally expressed non-immunodominant antigens in the joint.
As such, it was not surprising that we were unable to detect
significant cytokine production after direct incubation (without
using any pre- or co-stimulation) of PBMC with the peptides
derived from aggrecan, fibrillin, and MMP-3. The expected pre-
cursor frequency of these T cells will be low and involve low-
avidity self-specific T cells [49]. This problem was overcome
via generation of short-term peptide-specific T-cell lines in
selected patients. Using this method, we were able to confirm
the reality of the recorded T-cell proliferative responses and
show that T cells indeed are activated and do secrete
cytokines.
With the identification of self-epitopes that are recognized in
patients with JIA, we may now use techniques like T-cell cap-
ture or tetramer staining [50-52] to sort the antigen-specific T
cells directly and explore their qualities. Given that we expect
the responding T cells to be low-affinity T cells, the use of
tetramers will present difficulties. The T-cell capture tech-
nique, however, exploits so-called 'artificial APCs' (antigen-
presenting cells) that contain high numbers of MHC-peptide
complexes (signal 1) and include the presence of co-stimula-
tory molecules at the constructed MHC molecules (signal 2)
[52]. This reflects the in vivo situation and indeed may allow
binding of high-affinity as well as low-affinity T cells [52].
Conclusion
This study identifies a triplet of self-epitopes that are derived
from the joint-related antigens aggrecan, fibrillin, and MMP-3
that are recognized in patients with JIA. Immune reactivity to
the aggrecan peptide is present in the oligoarticular and pol-
yarticular subtypes of JIA and this peptide may be a target of
primary autoreactivity. The fibrillin peptide, to our knowledge,
is the first identified autoantigen specifically recognized in the
polyarticular subtype of JIA. The peptide derived from MMP-3
elicits significant immune responses in chronic arthritis and in
healthy controls. Further studies will be necessary to yield a
more detailed view of the role of these peptides in the patho-
genesis of JIA.
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